Evgeny Ledin

486 total citations
9 papers, 12 citations indexed

About

Evgeny Ledin is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Evgeny Ledin has authored 9 papers receiving a total of 12 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Cancer Research and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Evgeny Ledin's work include Cancer Genomics and Diagnostics (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Evgeny Ledin is often cited by papers focused on Cancer Genomics and Diagnostics (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Evgeny Ledin collaborates with scholars based in Russia, Australia and Austria. Evgeny Ledin's co-authors include I. Bazin, В. В. Бредер, Lev Demidov, Maxim Ivanov, David Berz, Piotr Serwatowski, A. Jeanson, Teresa Macarulla, Anastasia Mochalova and Céline Mascaux and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Immunotherapy.

In The Last Decade

Evgeny Ledin

5 papers receiving 10 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evgeny Ledin Russia 3 5 5 4 4 3 9 12
Аbay Baigenzhin Kazakhstan 3 3 0.6× 3 0.6× 4 1.0× 3 1.0× 14 11
Tsvetomir Ivanov Bulgaria 2 3 0.6× 5 1.0× 2 0.5× 8 2.0× 1 0.3× 7 13
Luca Tirloni Italy 2 3 0.6× 10 2.0× 4 1.0× 1 0.3× 4 1.3× 6 16
Shakthi Kumaran Ramasamy United States 3 2 0.4× 3 0.6× 10 2.5× 4 1.0× 1 0.3× 12 29
Chengrong Mi China 4 7 1.4× 4 0.8× 1 0.3× 7 1.8× 9 3.0× 8 30
Jawad Khamis Bahrain 3 5 1.0× 5 1.0× 11 2.8× 6 2.0× 6 18
Osama Mohamed Elsanousi Sudan 3 2 0.4× 7 1.4× 4 1.0× 6 2.0× 5 13
F Moura Brazil 1 5 1.0× 7 1.4× 3 1.0× 2 9
Beatriz Moya Spain 3 3 0.6× 6 1.2× 6 1.5× 9 3.0× 10 32
Saianand Balu India 3 4 0.8× 3 0.6× 10 2.5× 1 0.3× 2 0.7× 5 20

Countries citing papers authored by Evgeny Ledin

Since Specialization
Citations

This map shows the geographic impact of Evgeny Ledin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Ledin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Ledin more than expected).

Fields of papers citing papers by Evgeny Ledin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgeny Ledin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Ledin. The network helps show where Evgeny Ledin may publish in the future.

Co-authorship network of co-authors of Evgeny Ledin

This figure shows the co-authorship network connecting the top 25 collaborators of Evgeny Ledin. A scholar is included among the top collaborators of Evgeny Ledin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgeny Ledin. Evgeny Ledin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
2.
Meyer, Tim, Evgeny Ledin, Dong‐Wan Kim, et al.. (2022). Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 40(4_suppl). 434–434. 2 indexed citations
3.
Ledin, Evgeny, et al.. (2022). The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy.. Journal of Clinical Oncology. 40(16_suppl). e21512–e21512. 4 indexed citations
4.
5.
Girard, N., Martin Wermke, Evgeny Ledin, et al.. (2021). 532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours. Annals of Oncology. 32. S597–S597. 1 indexed citations
6.
Бредер, В. В., et al.. (2021). Практические рекомендации по лекарственному лечению билиарного рака. Malignant tumours. 10(3s2-1). 470–486. 3 indexed citations
7.
Ledin, Evgeny, et al.. (2021). Clinical application of next-generation sequencing in cancer patients.. Journal of Clinical Oncology. 39(15_suppl). e15090–e15090.
8.
9.
Хамошина, М.Б., et al.. (2017). CIMICIFUGA RACEMOSA EXTRACT AS AN ALTERNATIVE TO HORMONE THERAPY IN THE MANAGEMENT OF ESTROGEN DEFICIENCIES. Meditsinskiy sovet = Medical Council. 132–135.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Аbay Baigenzhin Breakdown of academic impact, for papers by Tsvetomir Ivanov Breakdown of academic impact, for papers by Luca Tirloni Breakdown of academic impact, for papers by Shakthi Kumaran Ramasamy Breakdown of academic impact, for papers by Chengrong Mi Breakdown of academic impact, for papers by Jawad Khamis Breakdown of academic impact, for papers by Osama Mohamed Elsanousi Breakdown of academic impact, for papers by F Moura Breakdown of academic impact, for papers by Beatriz Moya Breakdown of academic impact, for papers by Saianand Balu
Rankless by CCL
2026